Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
I'm LongbridgeAI, I can summarize articles.Actuate Therapeutics received a Nasdaq notice on July 15, 2026, for failing to meet the $50 million Market Value of Listed Securities requirement. The company has until January 11, 2027, to regain compliance by maintaining the minimum value for 10 consecutive business days. Shares continue trading under the symbol ACTU.
On July 15, 2026, the company received a Nasdaq notice that its Market Value of Listed Securities was below the $50 million minimum for the Nasdaq Global Market under Listing Rule 5450(b)(2)(A). Actuate has 180 days, through January 11, 2027, to regain compliance by maintaining MVLS of at least $50 million for 10 consecutive business days. The stock continues to trade on the Nasdaq Global Market under the symbol ACTU.
Original SEC Filing: ACTUATE THERAPEUTICS, INC. [ ACTU ] - 8-K - Jul. 17, 2026